

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Nouveau Life Pharmaceuticals, Inc.

370 Amapola Ave., Suite 200-A
Torrance, CA 90501

424-358-1046
invest@cbdxfund.com
2860

Quarterly Report
For the Period Ending: 06/30/2022
(the "Reporting Period")

As of 06/30/2022, the number of shares outstanding of our Common Stock was: 6,660,963,733

As of 03/31/2022, the number of shares outstanding of our Common Stock was: 10,278,851,733

As of 12/31/2021, the number of shares outstanding of our Common Stock was: 10,278,851,733

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

The name of issuer is Nouveau Life Pharmaceuticals, Inc.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

The issuer was incorporated on September 5, 1993 as a Nevada corporation and is headquartered in Wilton, CT 06897.

The issuer is incorporated in the State of Nevada in good standing and "Active".

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

As of the date this report was filed, the Company has engaged legal counsel in the State of Nevada to review the shareholder list and identify any outstanding common stock issued in certificate form that might possibly be eliminated. The Company will take appropriate action based on the results of the review.

The Company plans to acquire an operating company via reverse merger in the 4th quarter of 2021. The operating company and terms of a transaction have not yet been determined.

The address(es) of the issuer's principal executive office:

Nouveau Life Pharmaceuticals, Inc
370 Amapola Ave., Suite 200-A
Torrance, CA 90501

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address:

Nouveau Life Pharmaceuticals, Inc.
370 Amapola Ave., Suite 200-A
Torrance, CA 90501

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

2) Security Information

Trading symbol: NOUV
Exact title and class of securities outstanding: Common Stock

CUSIP: 66979K103
Par or stated value: 0.001
Total shares authorized: 11,000,000,000 as of date: 06/30/2022
Total shares outstanding: 6,660,963,733 as of date: 06/30/2022
Number of shares in the Public Float²: 6,101,314,475 as of date: 06/30/2022
Total number of shareholders of record: 277 as of date: 06/30/2022

All additional class(es) of publicly traded securities (if any):

Trading symbol: N/A
Exact title and class of securities outstanding: Series A Convertible Super Preferred Stock
CUSIP: N/A
Par or stated value: 0.001
Total shares authorized: 10,000,000 as of date: 06/30/2022
Total shares outstanding: 500 as of date: 06/30/2022

Transfer Agent

Name: Pacific Stock Transfer Company
Phone: 800-785-7782
Email: paul@pacificstocktransfer.com
Address: 6725 Via Austi Parkway, Suite 300, Las Vegas, NV 89119

Is the Transfer Agent registered under the Exchange Act?³ Yes: No:

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuance of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Shares Outstanding as of Second Most Recent Fiscal Year End:

Opening Balance

*Right-click the rows below and select "Insert" to add rows as needed.

Date 12/31/2019 Common:

10,278,851,733

Preferred:

10,000,000

Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or canceled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>7/20/2021</u>	<u>New Issuance</u>	<u>500</u>	<u>Preferred</u>	<u>N/A</u>	<u>No</u>	<u>CED Capital controlled by Frank I Igwealor</u>	<u>Operating Capital</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>7/20/2021</u>	<u>Cancellation</u>	<u>(10,000,000)</u>	<u>Preferred</u>	<u>N/A</u>	<u>No</u>	<u>Board Resolution</u>	<u>Board Resolution</u>	<u>N/A</u>	<u>N/A</u>
<u>3/7/2022</u>	<u>New Issuance</u>	<u>450,000,000</u>	<u>Common</u>	<u>0.00004</u>	<u>No</u>	<u>Frank I Igwealor</u>	<u>Operating Capital</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>3/11/2022</u>	<u>Cancellation</u>	<u>(4,067,888,000)</u>	<u>Common</u>	<u>N/A</u>	<u>No</u>	<u>Court Order</u>	<u>Court Order</u>	<u>Court Order</u>	<u>Court Order</u>
<u>4/8/2022</u>	<u>Cancellation</u>	<u>(500)</u>	<u>Preferred</u>	<u>N/A</u>	<u>No</u>	<u>N/A</u>	<u>Mergers and Acquisition</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>4/8/2022</u>	<u>New Issuance</u>	<u>500</u>	<u>Preferred</u>	<u>N/A</u>	<u>No</u>	<u>Young Ju Kim</u>	<u>Mergers and Acquisition</u>	<u>Restricted</u>	<u>Rule 144</u>

Shares Outstanding on Date of This Report:

Ending Balance

Ending Balance:

Date 06/30/2022

Common: 6,660,963,733

Preferred: 500

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended September 30, 2020, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2018 through September 30, 2020 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

- 1) As of June 30, 2022, no Officers or Directors other than those disclosed above and none of the control persons related to current management owned shares of any class of stock.

- 2) As of the date this report was filed, Frank I Igwealor owns and controls Community Economic Development Capital, LLC. (CED Capital), a California limited liabilities company, with an address at 370 Amapola Ave., Suite 200-A, Torrance, CA 90501. CED Capital owns Five Hundred (500) shares of the Company's Series A Preferred Stock, which represents 100% of the issued and outstanding shares. The Five Hundred (500) shares of Series A Preferred Stock collectively have super voting rights and each share can be converted into 200,000,000 shares of common stock.
- 3) On April 8, 2022, pursuant to a validly executed Securities Purchase Agreement, Mr. Young Ju Kim acquired the control block of the 500 Series A preferred shares has control of the Company through super voting rights over all classes of stock and the 500 Series A preferred shares are convertible into 100,000,000,000 (500 Series A preferred shares multiplied by 200,000,000) shares of the Company's common stock. Subsequently, Mr. Young merged one of his businesses, DNAgo.ai into the Company as an operating subsidiary. The company operates a platform that provides healthcare solution that realizes non-face-to-face care services.

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
<u>4/08/2022</u>	<u>200,000</u>	<u>200,000</u>	<u>N/A</u>	<u>4/08/2024</u>	<u>75% of the lowest market closing price for the Common Stock in the previous 25-days.</u>	<u>CED Capital</u>	<u>Merger</u>
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

N/A

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
- IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: **Sang Tae Choi**
Title: **President and CEO**
Relationship to Issuer: **Company Officer and Director**

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
- D. Statement of income;
- E. Statement of cash flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

Documents C-G are incorporated herein.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The Company provides a A Platform for Remote Senior Care. With NOUV platform, you can monitor all of your patients at a glance. You can of course also monitor details of each patient by just clicking on them. In the case of an emergency, NOUV will detect it before you do. The company is also close to rolling out its robotic and Ai based healthcare devices and wearable.

B. Please list any subsidiaries, parents, or affiliated companies.

Seniorgo.ai

C. Describe the issuers' principal products or services.

NOUV.ai is the Company's website. The Company provides a A Platform for Remote Senior Care. With NOUV platform, you can monitor all of your patients at a glance. You can of course also monitor details of each patient by just clicking on them. In the case of an emergency, NOUV will detect it before you do. The company is also close to rolling out its robotic and Ai based healthcare devices and wearables.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

3580 Wilshire Blvd.
Suite 100
Los Angeles, CA 90010

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Sang Tae Choi</u>	<u>President, CEO and Director</u>	<u>Carson, California</u>	<u>See Below (1)(2)</u>	<u>See Below (1)(2)</u>	<u>See Below (1)(2)</u>	<u>See Below (1)(2)</u>
<u>Young Ju Kim</u>	<u>Owner of more than 5%</u>	<u>Carson, California</u>	<u>500</u>	<u>Preferred</u>	<u>100</u>	<u>_____</u>
<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>
<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>
<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>

1). As of June 30, 2022 , no Officers or Directors other than those disclosed above and none of the control persons related to current management owned shares of any class of stock.

2). As of the date this report was filed, Frank I Igwealor owns and controls Community Economic Development Capital, LLC. (CED Capital), a California limited liabilities company, with an address at 370 Amapola Ave., Suite 200-A, Torrance, CA 90501. CED Capital owns Five Hundred (500) shares of the Company's Series A Preferred Stock, which represents 100% of the issued and outstanding shares. The Five Hundred (500) shares of Series A Preferred Stock collectively have super voting rights and each share can be converted into 200,000,000 shares of common stock.

3). On April 8, 2022, pursuant to a validly executed Securities Purchase Agreement, Mr. Young Ju Kim acquired the control block of the 500 Series A preferred shares has control of the Company through super voting rights over all classes of stock and the 500 Series A preferred shares are convertible into 100,000,000,000 (500 Series A preferred shares multiplied by 200,000,000) shares of the Company's common stock. Subsequently, Mr. Young merged one of his businesses, DNAgo.ai into the Company as an operating subsidiary. The company operates a platform that provides healthcare solution that realizes non-face-to-face care services.

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

No

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

No

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

No

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

N/A

9) **Third Party Providers**

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Udo Ekekeulu, Esq.
Firm: Alpha Advocate Law Group PC
Address 1: 11432 South Street, #373, Cerritos, CA 90703.
Address 2:
Phone: 310-866-6018
Email: alphaadvocatelaw@gmail.com

Accountant or Auditor

Name: N/A
Firm: N/A
Address 1: N/A
Address 2: N/A
Phone: N/A
Email: N/A

Investor Relations

Name: N/A

Firm: N/A
Address 1: N/A
Address 2: N/A
Phone: N/A
Email: N/A

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: N/A
Firm: N/A
Nature of Services: N/A
Address 1: N/A
Address 2: N/A
Phone: N/A
Email: N/A

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Sang Tae Choi certify that:

1. I have reviewed this Quarterly Disclosure Statement of Nouveau Life Pharmaceuticals, Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

3/24/2023

/S/ Sang Tae Choi

President and CEO

Principal Financial Officer:

I, Sang Tae Choi certify that:

1. I have reviewed this Quarterly Disclosure Statement of Nouveau Life Pharmaceuticals, Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

3/24/2023

/s/ Sang Tae Choi

Treasurer, Chief Financial Officer

Nouveau Life Pharmaceuticals, Inc.
INDEX TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

	<u>Page</u>
Financial Statements	
Unaudited Consolidated Balance Sheets as of June 30, 2022 and 2021	F-2
Unaudited Consolidated Statements of Operations for the Periods Ended June 30, 2022 and 2021	F-3
Unaudited Consolidated Statements of Stockholders' Deficit for the Periods Ended June 30, 2022 and 2021	F-4
Unaudited Consolidated Statements of Cash Flows for the Periods Ended June 30, 2022 and 2021	F-5
Notes to Unaudited Consolidated Financial Statements for the Periods Ended June 30, 2022 and 2021	F-6

Nouveau Life Pharmaceuticals, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

	June 30,	
	2022	2021
ASSETS		
Current Assets		
Cash	-	-
Prepaid expenses	-	-
TOTAL ASSETS	\$ -	\$ -
LIABILITIES & EQUITY		
Liabilities		
Current Liabilities	-	-
Long Term Liabilities	-	-
Total Liabilities	-	-
 Stockholders' deficit:		
<p>Preferred stock, \$.001 par value, 10,000,000 shares authorized, 500 issued and outstanding.</p> <p>Common Stock, \$.0001 par value, 11,000,000 shares authorized, 6,660,963,733 and 10,278,851,733 issued and outstanding as at June 30, 2022 and 2021 respectively.</p>		
	666,093	1,028,885
Additional Paid-in Capital	406,789	-
Accumulated Deficits	(1,028,885)	(1,028,885)
Total Equity	-	-
TOTAL LIABILITIES & EQUITY	-	-

The accompanying notes are an integral part of these financial statements.

F-2

Nouveau Life Pharmaceuticals. Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

	For the Period Ended June 30,	
	2022	2021
Ordinary Income/Expense		
Revenue		
Sales	\$ -	\$ -
Cost of Goods Sold	-	-
Gross Profit	-	-
Operating Expense	-	-
Employee compensation and benefits	-	-
Stock-based compensation	-	-
Occupancy and equipment	-	-
Advertising	-	-
Professional fees	-	-
Depreciation and amortization	-	-
Total operating expenses	-	-
Operating Loss		
Other Income		
Interest income	-	-
Interest expense	-	-
Total Other Income (Expense)	-	-
Net Income Adjustments		
NET COMPREHENSIVE LOSS	\$ -	\$ -
BASIC AND DILUTED LOSS PER SHARE:		
Net loss per common share - basic and diluted	\$ -	\$ -
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:		
Basic	10,278,851,733	10,278,851,733

The accompanying notes are an integral part of these financial statements.

F-3

Nouveau Life Pharmaceuticals, Inc.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

(UNAUDITED)

	Preferred Stock		Common Stock		Additional		TOTAL
	# of Shares	Amount	# of Shares	Amount	Paid-in	Accumulated	
					Capital	Deficit	
Balance - January 31, 2018	10,000,000	\$1,000	10,278,851,733	\$1,027,885	\$0	\$(1,028,885)	\$0
Net Income(Loss) - December 31, 2018		- -					\$0
Balance - December 31, 2018	10,000,000	\$1,000	10,278,851,733	\$1,027,885	\$0	\$(1,028,885)	\$0
Net Income(Loss) - December 31, 2019							
Balance - December 31, 2019	10,000,000	\$1,000	10,278,851,733	\$1,027,885	\$0	\$(1,028,885)	\$0
Net Income(Loss) - December 31, 2020							
Balance - December 31, 2020	10,000,000	\$1,000	10,278,851,733	\$1,027,885	\$0	\$(1,028,885)	\$0
Net Income(Loss) – June 30, 2022							
Balance - June 30, 2022	10,000,000		10,278,851,733	\$1,027,885	\$0	\$(1,028,885)	\$0

The accompanying notes are an integral part of these financial statements.

F-4

Nouveau Life Pharmaceuticals, Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

For the Period Ended June 30,

2022

2021

Cash Flows from Operating Activities:

Net income(loss)	\$	-	\$	-
Adjustments to reconcile net income(loss) to net cash used in operating activities		-		-

Depreciation and amortization		-		-
-------------------------------	--	---	--	---

Accretion of debt discounts		-		-
-----------------------------	--	---	--	---

Stock-based transaction expense		-		-
---------------------------------	--	---	--	---

Loss on disposed fixed assets		-		-
Changes in operating assets and liabilities		-		-

Net Cash Used In Operating Activities		-		-
--	--	---	--	---

Cash Flows from Investing Activities:

Purchases of property and equipment		-		-
-------------------------------------	--	---	--	---

Acquisition of assets		-		-
-----------------------	--	---	--	---

Net Cash Provided By Investing Activities		-		-
--	--	---	--	---

Cash Flows from Financing Activities:

Proceeds from issuance of common stock		-		-
--	--	---	--	---

Proceeds from issuance of warrants		-		-
------------------------------------	--	---	--	---

Proceeds from issuance of preferred stock		-		-
---	--	---	--	---

Proceeds from issuance of long-term debt		-		-
--	--	---	--	---

Proceeds from note payables		-		-
-----------------------------	--	---	--	---

Net Cash Provided By Financing Activities		-		-
--	--	---	--	---

Foreign Currency Translation

Net Change in Cash		-		-
---------------------------	--	---	--	---

Cash and Cash Equivalents - Beginning of Year		-		-
--	--	---	--	---

Cash and Cash Equivalents - End of Year	\$	-	\$	-
--	-----------	---	-----------	---

The accompanying notes are an integral part of these financial statements.

F-5

Nouveau Life Pharmaceuticals, Inc.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2022
(Unaudited)

NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS

Nouveau Life Pharmaceuticals, Inc. (the “Company”) formerly known Polo Equities, Inc., was incorporated in May 1998, pursuant to the laws of the State of Nevada. The Company used to be a developer of hardware solutions for the Municipal Lighting, Building Automation, HVAC, Indoor Lighting, Sub-metering and many other applications. Its products encompassed inside and outside lighting, HVAC, advanced metering and various other building automations requirements.

The Company had abandoned its business and failed to take steps to dissolve, liquidate and distribute its assets. It had also failed to meet the required reporting requirements with the Nevada Secretary of State, hold an annual meeting of stockholders and pay its annual franchise tax from September 2019 to 2021 which resulted in its Nevada charter being revoked. The Company also failed to provide adequate current public information as defined in Rule 144, promulgated under the Securities Act of 1933, and was thus subject to revocation by the Securities and Exchange Commission pursuant to Section 12(k) of the Exchange Act. On June 23, 2021, a shareholder filed a petition for custodianship, with the District Court, Clark County, Nevada and was appointed as the custodian of the Company on July 20, 2021. The Company’s Nevada charter was reinstated on July 21, 2021, and all required reports were filed with the State of Nevada soon after. The Company remains active as of the date of this report and is currently taking steps to provide adequate current public information to meet the requirements under the Securities Act of 1933. The custodian was not able to recover most of the Company’s accounting records from previous management but was able to get a balance sheet, debt schedules, and the shareholder information hence the Company’s outstanding common shares were reflected in the equity section of the accompanying unaudited financial statements for fiscal year ended 2020 and 2019, and for the quarters ending March 31, 2021, and June 30, 2022.

Nouveau Life Pharmaceuticals, Inc. (the “Company”) formerly known Polo Equities, Inc., was incorporated in Nevada in May 1998, pursuant to the laws of the State of Nevada.

The company incurred operating losses over the years until it stopped reporting on June 15, 2017, resulting in accumulated deficit of \$813,360 as at December 31, 2016. After their quarterly reports of June 15, 2017, the Company stopped all forms of making public report of its operation and financial results.

On June 11, 2021, Alpharidge Capital, LLC, a shareholder of the Company, served a demand to the Company, at last address of record, to comply with the Nevada Secretary of State statues N.R.S. 78.710 and N.R.S. 78.150. On June 23, 2021, a petition was filed against the Company in the District Court of Clark County, Nevada, entitled “In the Matter of International Star, Inc., a Nevada corporation” under case number A-21-836831-C by Alpharidge Capital, LLC, along with an Application for Appointment of Custodian, after several attempts to GET prior management to reinstate the Company’s Nevada charter, which had been revoked.

On July 20, 2021, the District Court of Clark County, Nevada entered an Order Granting Application for Appointment of Alpharidge Capital, LLC (the “Order”), as Custodian of the Company. Pursuant to the Order, the Alpharidge Capital, LLC (the “Custodian”) has the authority to take any actions on behalf of the Company, that are reasonable, prudent or for the benefit of pursuant to, including, but not limited to, issuing shares of stock and issuing new classes of stock, as well

as entering in contracts on behalf of the Company. In addition, the Custodian, pursuant to the Order, is required to meet the requirements under the Nevada charter.

On July 20, 2021, pursuant to a Securities Purchase Agreement (SPA) the Custodian granted to Community Economic Development Capital, LLC. (CED Capital), 500 Series A preferred shares (convertible at 1 into 200,000,000 common shares, and voting rights of 60% of all votes) in exchange for \$35,000 which the Company used to fund the reinstatement of the Company with the State of Nevada, settlement of the Stock Transfer Agent's balance. CED Capital also undertook to make all reasonable efforts to provide adequate current public information to meet the requirements under the Securities Act of 1933.

On July 20, 2021, the Custodian appointed Frank Ikechukwu Igwealor, who is associated to Alpharidge Capital, LLC., as the Company's sole officer, secretary, treasurer and director.

The purchaser of the 500 Series A preferred shares has control of the Company through super voting rights over all classes of stock and the 500 Series A preferred shares are convertible into 100,000,000,000 (500 Series A preferred shares multiplied by 200,000,000) shares of the Company's common stock. However, the court appointed control still remains with the Custodian until the Custodian files a petition with the District Court of Clark County, Nevada to relinquish custodianship and control of the Company.

On July 21, 2021, the Company filed a Certificate of Revival with the Secretary State of the State of Nevada, which reinstated the Company's charter and appointed a new Resident Agent in Nevada.

On April 8, 2022, pursuant to a validly executed Securities Purchase Agreement, Mr. Young Ju Kim acquired the control block of the 500 Series A preferred shares has control of the Company through super voting rights over all classes of stock and the 500 Series A preferred shares are convertible into 100,000,000,000 (500 Series A preferred shares multiplied by 200,000,000) shares of the Company's common stock. Subsequently, Mr. Young merged one of his businesses, DNAgo.ai into the Company as an operating subsidiary. The company operates a platform that provides healthcare solution that realizes non-face-to-face care services.

NOTE 2 – BASIS OF PRESENTATION AND GOING CONCERN

Basis of Presentation

The Company has earned insignificant revenues from limited principal operations. Accordingly, the Company's activities have been accounted for as those of a "Development Stage Enterprise" as set forth in Financial Accounting Standards Board Statement No. 7 ("SFAS 7"). Among the disclosures required by SFAS 7 are that the Company's financial statements be identified as those of a development stage company, and that the statements of operations, stockholders' equity (deficit) and cash flows disclose activity since the date of the Company's inception.

Basis of Accounting

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States. All intercompany transactions have been eliminated.

Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company currently has no operations with an accumulated deficit of \$1,028,885 as of June 30, 2022. The Company intends to commence operations as set out below and raise the necessary funds to carry out the aforementioned strategies. The Company cannot be certain that it will be successful in these strategies even with the required funding.

These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

For purposes of the statement of cash flows, cash equivalents include demand deposits, money market funds, and all highly liquid debt instruments with original maturities of three months or less.

Financial Instruments

The FASB issued ASC 820-10, Fair Value Measurements and Disclosures, for financial assets and liabilities. ASC 820-10 provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. ASC 820-10 defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

- Level 1: Quoted prices in active markets for identical assets or liabilities
- Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.
- Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Concentrations and Credit Risks

The Company's financial instruments that are exposed to concentrations and credit risk primarily consist of its cash, sales and accounts receivable. The Company places its cash and cash equivalents with financial institutions of high credit

worthiness. At times, its cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits. The Company's management plans to assess the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures are limited.

Foreign Currency Translation

The accounts of the Company are accounted for in accordance with the Statement of Financial Accounting Standards No. 52 ("SFAS 52"), "Foreign Currency Translation". The financial statements of the Company are translated into US dollars as follows: assets and liabilities at year-end exchange rates; income, expenses and cash flows at average exchange rates; and shareholders' equity at historical exchange rate.

Monetary assets and liabilities, and the related revenue, expense, gain and loss accounts, of the Company are re-measured at year-end exchange rates. Non-monetary assets and liabilities, and the related revenue, expense, gain and loss accounts are re-measured at historical rates. Adjustments which result from the re-measurement of the assets and liabilities of the Company are included in net income.

Share-Based Compensation

ASC 718, Compensation – Stock Compensation, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized in the period of grant.

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, Equity – Based Payments to Non-Employees. Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

As of June 30, 2022 and 2021, respectively, there was \$0.00 of unrecognized expense related to non-vested stock-based compensation arrangements granted. There have been no options granted during the three months ended June 30, 2022 and 2021, respectively.

Income Taxes

The Company accounts for income taxes under ASC 740, Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Deferred tax assets or liabilities were offset by a 100% valuation allowance, therefore there has been no recognized benefit as of June 30, 2022 and 2021, respectively. Further it is unlikely with the change of control that the Company will have the ability to realize any future tax benefits that may exist.

Commitments and Contingencies

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

Earnings Per Share

Net income (loss) per share is calculated in accordance with ASC 260, Earnings Per Share. The weighted-average number of common shares outstanding during each period is used to compute basic earnings or loss per share. Diluted earnings or loss per share is computed using the weighted average number of shares and diluted potential common shares outstanding. Dilutive potential common shares are additional common shares assumed to be exercised.

Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding at June 30, 2022 and 2021. Due to net operating loss, there is no presentation of dilutive earnings per share, as it would be anti-dilutive.

Forgiveness of Indebtedness

The Company follows the guidance of AS 470.10 related to debt forgiveness and extinguishment. Debts of the Company are considered extinguished when the statute of limitations in the applicable jurisdiction expires or when terminated by judicial authority such as the granting of a declaratory judgment. Debts to related parties or shareholders are treated as capital transactions when forgiven or extinguished and credited to additional paid in capital. Debts to non-related parties are treated as other income when forgiven or extinguished.

Recent Accounting Pronouncements

We have reviewed all the recently issued, but not yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company.

In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815), which changes both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results, in order to better align an entity's risk management activities and financial reporting for hedging relationships. The amendments expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. FASB ASU No. 2017-12 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, with early adoption permitted. We are still evaluating the impact that this guidance will have on our financial position or results of operations, and we have not yet determined whether we will early adopt FASB ASU No. 2017-12.

In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This guidance changes how companies account for certain aspects of share-based payments to employees. Among other things, under the new guidance, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in-capital ("APIC"), but will instead record such items as income tax expense or benefit in the income statement, and APIC pools will be eliminated. Companies will apply this guidance prospectively. Another component of the new guidance allows companies to make an accounting policy election for the impact of forfeitures on

the recognition of expense for share-based payment awards, whereby forfeitures can be estimated, as required today, or recognized when they occur. If elected, the change to recognize forfeitures when they occur needs to be adopted using a modified retrospective approach. All of the guidance will be effective for the Company in the fiscal year beginning January 1, 2018. Early adoption is permitted. The Company is currently evaluating the impact of this guidance, if any, on its financial statements and related disclosures.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which establishes new accounting and disclosure requirements for leases. FASB ASU No. 2016-02 requires lessees to classify most leases as either finance or operating leases and to initially recognize a lease liability and right-of-use asset. Entities may elect to account for certain short-term leases (with a term of 12 months or less) using a method similar to the current operating lease model. The statements of operations will include, for finance leases, separate recognition of interest on the lease liability and amortization of the right-of-use asset and for operating leases, a single lease cost, calculated so that the cost of the lease is allocated over the lease term on a straight-line basis. While we are in the early stages of our implementation process for FASB ASU No. 2016-02, and have not yet determined its impact on our financial position or results of operations, these leases would potentially be required to be presented on the balance sheet in accordance with the requirements of FASB ASU No. 2016-02. FASB ASU No. 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, with early adoption permitted. FASB ASU No. 2016-02 must be applied using a modified retrospective approach, which requires recognition and measurement of leases at the beginning of the earliest period presented, with certain practical expedients available.

In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The guidance requires an entity to measure inventory at the lower of cost or net realizable value, which is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation, rather than the lower of cost or market in the previous guidance. This amendment applies to inventory that is measured using first-in, first-out (FIFO). This amendment is effective for public entities for fiscal years beginning after December 15, 2016, including interim periods within those years. A reporting entity should apply the amendments prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the impact of this guidance, if any, on its financial statements and related disclosures.

In June 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. generally accepted accounting principles when it becomes effective. In July 2015, the FASB deferred the effective date of the standard by an additional year; however, it provided companies the option to adopt one year earlier, commensurate with the original effective date. Accordingly, the standard will be effective for the Company in the fiscal year beginning January 1, 2018, with an option to adopt the standard for the fiscal year beginning January 1, 2017. The Company is currently evaluating this standard and has not yet selected a transition method or the effective date on which it plans to adopt the standard, nor has it determined the effect of the standard on its financial statements and related disclosures.

NOTE 4 - INCOME TAXES

Income taxes are provided based upon the liability method. Under this approach, deferred income taxes are recorded to reflect the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year-end. A valuation allowance is recorded against deferred tax assets if management does not believe the Company has met the “more likely than not” standard imposed by accounting standards to allow recognition of such an asset.

Deferred tax assets/liabilities were as follows as of June 30, 2022 and 2021:

<u>Description</u>	<u>30-Jun-21</u>	<u>30-Jun-20</u>
Net operating loss carry forward	1,028,885	1,028,885
Valuation allowance	(1,028,885)	(1,028,885)
Total	\$ - g	\$ -

As of June 30, 2022, the Company expected no net deferred tax assets to be recognized, resulting from net operating loss carry forwards. Deferred tax assets were offset by a corresponding allowance of 100%.

The Company experienced a change in control during the year, and therefore no more than an insignificant portion of this net operating allowance will ever be used against future taxable income.

NOTE 5 – NOTES PAYABLE – RELATED PARTIES

The following notes payable were from related parties:

NOTE 6 – NOTES PAYABLE

None

NOTE 7 - COMMITMENTS AND CONTINGENCIES

Risks and Uncertainties

The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure.

The Company has entered into no contracts during the year as follows:

Legal and other matters

In the normal course of business, the Company may become a party to litigation matters involving claims against the Company. The Company's management is aware of a garnishment order that was previously served to the Company's Stock Transfer Agents. The Company's attorneys are reviewing the garnishment order to ascertain its implication to the company's financial statements. Aside from the court order discussed above, The Company's management is unaware of any pending or threatened assertions and there are no current matters that would have a material effect on the Company's financial position or results of operations.

NOTE 8 - SUBSEQUENT EVENTS

Management has evaluated subsequent events through the date of filing the consolidated financial statements with OTC Markets, the date the consolidated financial statements were available to be issued. Management is not aware of any significant events that occurred subsequent to the balance sheet date that would have a material effect on the consolidated financial statements thereby requiring adjustment or disclosure, other than those noted below:

On April 8, 2022, pursuant to a validly executed Securities Purchase Agreement, Mr. Young Ju Kim acquired the control block of the 500 Series A preferred shares has control of the Company through super voting rights over all classes of

stock and the 500 Series A preferred shares are convertible into 100,000,000,000 (500 Series A preferred shares multiplied by 200,000,000) shares of the Company's common stock. Subsequently, Mr. Young merged one of his businesses, DNago.ai into the Company as an operating subsidiary. The company operates a platform that provides healthcare solution that realizes non-face-to-face care services.